Naomi Kiyota

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 4.9K citations · Full text

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2K citations · Full text

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

Yoshinori Imamura, Toru Mukohara, Yohei Shimono et al. · Oncology Reports · 2015 · 834 citations · Full text

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 776 citations · Full text

Neoadjuvant Therapy, Checkmate 141, Medicine +9

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein et al. · The Lancet Oncology · 2017 · 417 citations · Full text

Oncology, Neoadjuvant Therapy, Checkmate 141 +11